~~<i id='C6C55FF3D3'><strike id='C6C55FF3D3'><tt id='C6C55FF3D3'><pre id='C6C55FF3D3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：leisure time 2025-08-24 09:37:49 - browse：49

People taking notes while sitting around a meeting table — Adobe

It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Being 'nonadherent' patient made me a more empathetic doctor

explore

entertainment

focus

knowledge

hotspot

entertainment

“Obtainingandmaintainingajobisacriticalpartofanyrecoveryjourney,"saidRahulGupta,theWhiteHousedrugcza

WSS

Type 2 diabetes prevention programs work at large scale: study

Carbon Health diabetes program, a test of data

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Security flaws in third

What affirmative action's end means to a medical student

UpToDate has a racism problem: Dr. Stanley Goldfarb

explore

focus

explore

Jerome Adams on the need for new antivirals for Covid

Vertex cell therapy lets patients with type 1 diabetes stop insulin

As demand for Covid shots wanes, Moderna seeks its next success

Type 2 diabetes prevention programs work at large scale: study

Apple is now the first public company to be valued at $3 trillion

A letter from the executive editor: STAT UnitedHealth investigation

Psychedelics group wrestles with new pharma identity

Study suggests Covid rebound is far more common with Paxlovid than without

23andMe had bad news about my health. I wish a person had delivered it

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

entertainment

Today's health inequities arise from racist U.S. history, say experts

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

AstraZeneca lung cancer study comes in below expectations

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

FDA reorg will put new emphasis on investigations, sources say

How state and local governments are sidelining science

focus

knowledge

hotspot

entertainment